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Opioid Treatment Agreements and Patient Accountability 
 
Abstract: 
Opioid treatment agreements are written agreements between physicians and patients 
enumerating the risks associated with opioid medications along with the requirements that 
patients must meet to receive these medications on an ongoing basis. The choice to use such 
agreements goes beyond the standard informed consent process, and has a distinctive symbolic 
significance.  Specifically, it suggests that physicians regard it as important to hold their patients 
accountable for adhering to various protocols regarding the use of their opioid medications. After 
laying out a taxonomy of accountability relationships between physicians and patients, I argue 
that opioid treatment agreements are only justifiable for physicians to use in their provision of 
care if they improve public health outcomes, which has yet to be demonstrated. 
 
Opioid treatment agreements are an increasingly prevalent part of pain treatment as 
physician concerns about opioid prescribing have grown.1 These documents are written 
agreements between physicians and patients enumerating the risks associated with opioid 
medications and the requirements that patients must meet to receive these medications on an 
ongoing basis. The choice to use opioid treatment agreements goes beyond the standard informed 
consent process, and has a distinctive symbolic significance.  Specifically, it suggests that 
physicians regard it as important to hold their patients accountable for adhering to various 
protocols regarding the use of their opioid medications. 
The American Academy of Pain Medicine recommends the use of these agreements, 
particularly for patients deemed at high risk of developing opioid use disorder. They provide a 
template agreement for physicians that explicitly uses the language of accountability: “Because 
these medications have the potential for abuse or diversion...strict accountability is necessary for 
both medical safety and legal reasons. Therefore, the following policies are agreed to by you, the 
patient, to help me keep you safe and to provide you with good care.”2 How should we 
understand what it means for physicians to hold their patients accountable in this context? After 
laying out a taxonomy of accountability relationships between physicians and patients, I argue 
that opioid treatment agreements are only justifiable for physicians to use in their provision of 
care if they improve public health outcomes, which has yet to be demonstrated. 
Holding Patients Responsible vs. Shallowly Accountable 
On one possible view, physicians use opioid treatment agreements to hold their patients 
responsible for taking and otherwise handling opioid medications exactly as prescribed. Holding 
someone responsible entails several things: First, you regard her as subject to a norm or 
expectation. Second, in holding her responsible, you are enforcing that norm with her. And 
finally, you see her as capable of understanding and being motivated by the grounds for that 
norm. For opioid treatment agreements, this would mean that (a) physicians regard their patients 
as subject to the expectations expressed in these agreements, (b) physicians are willing to enforce 
those norms and cut off access to opioid medications if their requirements are not met, and (c) 
physicians regard their patients as capable of understanding and being motivated by the concern 
that if they do not satisfy those expectations, they are at risk for developing addiction (among 
other health concerns).  
Rather than holding patients responsible, physicians using opioid treatment agreements 
might be said to be holding their patients accountable in a shallower sense. Holding someone 
shallowly accountable, like holding her responsible, involves the enforcement of a previously 
established norm that you regard the person as capable of understanding. A person can be (and 
be appropriately held) shallowly accountable whenever a norm applies, and she is able to 
understand that there is such a norm and act in accordance with it. This does not assume, 
however, that the person can understand or be motivated by the grounds for that norm. This 
would mean that physicians regard their patients as subject to the (enforceable) expectations 
expressed in opioid treatment agreements, but not necessarily because patients are able to 
appreciate or be motivated by the grounds for those expectations. Holding someone shallowly 
accountable is fundamentally a matter of incentivizing desirable behavior and disincentivizing 
undesirable behavior – in this case, incentivizing adherence and disincentivizing opioid abuse 
and diversion.  
Opioid treatment agreements generally include a description of the risks associated with 
treating pain using opioids, the sort of information that is important to informed consent to 
treatment. But these agreements also notably include various stipulations that patients must meet 
for their physician to continue to prescribe them opioids (see text box for examples of the terms 
of the American Academy of Pain Medicine template agreement, offered as guidance to 
institutions seeking to craft their own agreements).3 These stipulations cannot plausibly be 
understood as part of a method for holding patients responsible. An implicit assumption of 
opioid treatment agreements is that patients are unlikely to be adequately motivated to adhere to 
their physicians’ recommendations unless their access to opioids and perhaps even to their 
physician depends on their doing so. As such, these agreements do not satisfy condition (c) 
above. Opioid treatment agreements are better understood as a tool for physicians to hold their 
patients shallowly accountable (as opposed to holding them responsible) for satisfying the 
expectations described therein. 
Holding patients shallowly accountable is not intrinsically objectionable. Relationships, 
including physician-patient relationships, generally involve incentives to behave in certain ways. 
Insofar as we care about what others think of us, including our physicians, we will be motivated 
to live up to their expectations. As citizens, we are subject to legal requirements whether we 
understand their grounds or not, and in those circumstances, we are being held shallowly 
accountable for obeying the law. But the practice of holding others shallowly accountable aims 
solely at deterring them from committing harmful norm violations. The aims of holding someone 
shallowly accountable are therefore strictly instrumental. Accordingly, the interventions that are 
undertaken on these grounds must actually bring about a better outcome than the alternatives. If 
opioid treatment agreements are tools for physicians to hold their patients shallowly accountable 
(as I have argued), then the practice of using these treatment agreements is only justified if it is 
instrumental in improving public health outcomes.  
There is not, however, enough evidence that opioid treatment agreements promote patient 
adherence to justify their use. In a systematic review, Starrels et al. note that few studies have 
examined whether opioid treatment agreements reduce opioid misuse, and the evidence currently 
available to support this conclusion is relatively weak.4 Though absence of evidence is not to be 
confused with evidence of absence, physicians are not justified in holding patients shallowly 
accountable using strategies that have not been shown to be instrumentally effective. 
Challenges to the Effectiveness of Opioid Treatment Agreements 
In some ways, the lack of evidence supporting the effectiveness of opioid treatment 
agreements for promoting adherence is unsurprising. A survey of 162 opioid treatment 
agreements from 38 states showed that all of them assumed health literacy skills that surpass the 
average skills of American adults.5 If patients do not understand the content of these agreements, 
then they cannot be held accountable for adhering to them. In addition, if patients are simply 
given opioid treatment agreements but do not have any further conversations with their 
physicians about what the agreements say, then patients are unlikely to be aware of what their 
physicians expect of them and what the consequences will be of their violating their physicians’ 
expectations. Surveying a sample of HIV-infected indigent adults, Penko et al. found that many 
patients were almost no better than chance at identifying whether their physician had even given 
them an opioid treatment agreement.6 Though these agreements include various requirements 
that patients must meet to be prescribed opioids, they are not an adequate substitute for an honest 
conversation between physicians and patients about the risks and benefits of opioid treatment, 
not least of all because patients may feel pressured to sign these documents to access pain 
management without really understanding them. Some of these concerns would likely be 
ameliorated by constructing documents at an appropriate literacy level and discussing them in 
detail with patients. But given the typical constraints on physicians’ time and the fact that the 
requirements to use opioid treatment agreements often come from above (e.g., from state 
regulators) rather than from physicians themselves, they are worth noting nonetheless.  
In addition, it may be difficult for physicians to assess adherence. There is no single, 
cost-effective measure that will reliably determine whether a patient is abusing or diverting her 
opioid medication.7 Opioid treatment agreements often require patients to agree to random drug 
testing (most commonly using urine immunoassay), but there are substantial risks of both false 
positives and false negatives.8 Further confirmatory methods that improve physicians’ ability to 
correctly interpret urine or blood tests, or using hair analysis instead (which can indicate more 
about opioid usage over the long term), are significantly more expensive and are less available to 
physicians.9 This is not to say that urine drug tests have no clinical value, but to make significant 
decisions about patient care using tests that are known to be unreliable still raises ethical issues.  
Physicians should also be concerned about the symbolic significance of asking patients to 
sign opioid treatment agreements. Depending on how they are formulated, opioid treatment 
agreements may seem overly punitive, or express to patients that their physicians do not trust 
them. In one particularly extreme example, Fishman cites an agreement that asked patients to 
agree to be monitored by a private investigator if their physician suspects non-adherence.10 There 
is also the matter of how physicians determine when to use opioid treatment agreements, and 
when to enforce them.11 Physicians who elect to use or enforce these agreements only with 
patients they deem to be at high risk of developing addiction must be able to identify such 
patients without bias, and current evidence suggests that they may not.12 
Moving Forward 
In the current public health climate, there are substantial pressures on physicians and 
patients alike regarding opioid therapy. Responsible opioid prescribing is often equated with 
minimizing opioid prescribing as much as possible. While there are other, non-opioid treatments 
that are effective for many patients seeking pain management, there will likely remain some 
patients for whom opioids are clinically appropriate. Moreover, there are good reasons deriving 
from public health ethics to try to monitor these patients closely. One potential benefit of opioid 
treatment agreements is that they provide guidelines for patients regarding the risks and 
responsibilities connected to opioid therapy. Another is that they disclose the surveillance that 
physicians and regulators want to employ with patients on opioids for the sake of public health.13 
Assuming such treatment agreements were written at an appropriate literacy level, and that 
physicians were also willing to have substantive conversations to ensure their patients understand 
what is required for adherence, opioid treatment agreements could be protective for patients 
receiving a therapy likely to cause dependence and potentially addiction. But given the 
agreement structure, physicians could point to non-adherence as a reason to refuse to continue 
prescribing, or to dismiss patients from their practice. In such a circumstance, physicians do not 
seem to regard themselves as accountable to patients to help them manage their pain and receive 
appropriate care. Opioid treatment agreements are thus not a formal way of expressing the notion 
of accountability that is already part of physician-patient relationships, which is fundamentally 
mutual accountability. 
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Terms of Opioid Treatment Agreements 
 
Category:      Example from AAPM Template: 
Risks of improper use You must discuss the long-term use of controlled 
substances with your physician. Prolonged opioid 
use can be associated with serious health risks. 
You need to understand these risks.  
Surveillance and monitoring You must give the prescribing physician 
permission to discuss all diagnostic and treatment 
details with dispensing pharmacists or other 
professionals who provide your health care for 
purposes of maintaining accountability and 
coordinating your care.  
Limits on refilling or replacing medication You must agree that medications will not be 
replaced if they are lost, flushed down the toilet, 
destroyed, left on an airplane, etc. If your 
medication has been stolen and you complete a 
police report regarding the theft and present that 
report to the prescribing physician, an exception 
may be made at the discretion of your treating 
physician. 
Points of termination You understand and agree that failure to adhere to 
these policies will be considered noncompliance 
and may result in cessation of opioid prescribing 
by your physician and possible dismissal from this 
clinic.  
 
 
